MedTrace Logo

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

NCT00782470 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2014-11-03

No results posted yet for this study

Summary

Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the consequences of switching treatment in QoL (quality of life), development of target joints, activity level and reasons that might influence the desire to switch.

Conditions

  • Hematologic Disease
  • Blood Coagulation Disorders

Interventions

BEHAVIORAL

Recombinant Factor VIII (Kogenate, BAY 14-2222)

Subjects electing to stay on the prophylactic treatment (prospective)

BEHAVIORAL

Recombinant Factor VIII (Kogenate, BAY 14-2222)

Subjects electing to switch to on-demand treatment (prospective)

BEHAVIORAL

Recombinant Factor VIII (Kogenate, BAY 14-2222)

Subjects remaining on-demand treatment (retrospective)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
14 Years
Max Age
29 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States
  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00782470 on ClinicalTrials.gov